Platelet-rich plasma (PRP), also known as platelet enhanced plasma or platelet gel, is a blood plasma product that includes four to ten times the amount of platelets and growth factors found in normal blood. By releasing a large number of growth factors to the injury site, increased blood plasma concentration speeds up the healing process.
Drivers of the Global Platelet-Rich Plasma Market
Over the forecast period, the worldwide Platelet Rich Plasma Market is expected to develop due to an increase in cosmetic operations. According to the International Society of Aesthetic Plastic Surgery (ISAPS), 1,036,618 cosmetic treatments were performed in Mexico in 2018 while roughly 128,398 procedures were performed in Thailand.
Furthermore, the worldwide platelet-rich Platelet Rich Plasma Market is predicted to rise due to the high prevalence of sports injuries over the forecast period. According to the National High School Sports-Related Injury Surveillance Study 2017-2018, there were 1,367,490 sports-related injury cases reported in high schools across the United States.
Restraints in the Global Platelet-Rich Plasma Market
The worldwide Platelet Rich Plasma Market is projected to be hampered by uncertainty over the therapeutic efficacy of platelet-rich plasma. For example, a study published in Current Reviews in Musculoskeletal Medicine in 2018 found moderate high-quality evidence supporting the use of leukocyte-rich (LR)-PRP injection for patellar tendinopathy and PRP injection for plantar fasciitis and donor site pain in patellar tendon graft Bone-patellar tendon-bone anterior cruciate ligament reconstruction. Furthermore, the evaluation found insufficient evidence to recommend PRP for rotator cuff tendinopathy, hip osteoarthritis, or high ankle sprains on a routine basis.
Key Developments in the Global Platelet-Rich Plasma Market
Restraints in the Global Platelet-Rich Plasma Market
The worldwide Platelet Rich Plasma Market is projected to be hampered by uncertainty over the therapeutic efficacy of platelet-rich plasma. For example, a study published in Current Reviews in Musculoskeletal Medicine in 2018 found moderate high-quality evidence supporting the use of leukocyte-rich (LR)-PRP injection for patellar tendinopathy and PRP injection for plantar fasciitis and donor site pain in patellar tendon graft Bone-patellar tendon-bone anterior cruciate ligament reconstruction. Furthermore, the evaluation found insufficient evidence to recommend PRP for rotator cuff tendinopathy, hip osteoarthritis, or high ankle sprains on a routine basis.
Key Developments in the Global Platelet-Rich Plasma Market
To increase their market share, major competitors in the worldwide platelet-rich plasma market are focusing on partnership and collaboration strategies. For example, CollPlant, a regenerative medicine company, renewed its exclusive distribution agreement with Arthrex in March 2019 for Vergenix STR, an injectable gel made up of cross-linked bioengineered recombinant human type I collagen, rhCollagen, combined with autologous platelet-rich plasma for the treatment of tendinopathy.
0 Comments